Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genmab A/S

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

38 comunicati stampa

Guarda tutti i comunicati
24/10/2026
Multimedialità
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
23/10/2026
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Web e Social Network
Industria
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
05/10/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
03/10/2026
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
06/07/2026
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Industria
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
29/06/2026
Cardiologia
Terza età
Biotecnologia
Farmaceutica
Oncologia
Salute
Vetrine/Shopping
Medicina - Varie
Eventi
Industria
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
13/06/2026
Cardiologia
Terza età
Biotecnologia
Farmaceutica
Oncologia
Salute
Vetrine/Shopping
Medicina - Varie
Eventi
Industria
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
21/05/2026
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Eventi
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
13/04/2026
Industria
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
16/01/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0